...
search icon
vygr-img

Voyager Therapeutics Inc, Common Stock

VYGR

NSQ

$3.4

-$0.03

(-0.87%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$181.50M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
368.01K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.95
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.75 L
$9.55 H
$3.4

About Voyager Therapeutics Inc, Common Stock

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVYGRSectorS&P500
1-Week Return3.66%1.9%1.37%
1-Month Return5.92%1.36%15.76%
3-Month Return-20.19%-8.73%-2.58%
6-Month Return-36.57%-5.96%0.72%
1-Year Return-59.76%-7.97%12.24%
3-Year Return-46.54%3.54%52.73%
5-Year Return-73.64%34.17%100.37%
10-Year Return-80.85%78.8%180.28%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue171.13M37.41M40.91M250.01M80.00M[{"date":"2020-12-31","value":68.45,"profit":true},{"date":"2021-12-31","value":14.97,"profit":true},{"date":"2022-12-31","value":16.36,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":32,"profit":true}]
Cost of Revenue108.75M73.79M6.19M4.44M4.73M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":67.85,"profit":true},{"date":"2022-12-31","value":5.69,"profit":true},{"date":"2023-12-31","value":4.08,"profit":true},{"date":"2024-12-31","value":4.35,"profit":true}]
Gross Profit62.38M37.41M40.91M245.57M75.27M[{"date":"2020-12-31","value":25.4,"profit":true},{"date":"2021-12-31","value":15.24,"profit":true},{"date":"2022-12-31","value":16.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":30.65,"profit":true}]
Gross Margin36.45%100.00%100.00%98.22%94.09%[{"date":"2020-12-31","value":36.45,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.22,"profit":true},{"date":"2024-12-31","value":94.09,"profit":true}]
Operating Expenses143.74M111.03M91.74M127.99M163.29M[{"date":"2020-12-31","value":88.03,"profit":true},{"date":"2021-12-31","value":68,"profit":true},{"date":"2022-12-31","value":56.19,"profit":true},{"date":"2023-12-31","value":78.39,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income27.38M(73.62M)(50.84M)122.01M(83.29M)[{"date":"2020-12-31","value":22.44,"profit":true},{"date":"2021-12-31","value":-60.34,"profit":false},{"date":"2022-12-31","value":-41.66,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-68.26,"profit":false}]
Total Non-Operating Income/Expense11.02M2.03M6.24M23.45M37.28M[{"date":"2020-12-31","value":29.55,"profit":true},{"date":"2021-12-31","value":5.45,"profit":true},{"date":"2022-12-31","value":16.73,"profit":true},{"date":"2023-12-31","value":62.89,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income36.74M(71.20M)(46.39M)133.74M(64.34M)[{"date":"2020-12-31","value":27.47,"profit":true},{"date":"2021-12-31","value":-53.24,"profit":false},{"date":"2022-12-31","value":-34.69,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-48.11,"profit":false}]
Income Taxes(1.66M)(5.17M)16.00K1.41M665.00K[{"date":"2020-12-31","value":-117.83,"profit":false},{"date":"2021-12-31","value":-366.83,"profit":false},{"date":"2022-12-31","value":1.14,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":47.23,"profit":true}]
Income After Taxes38.40M(66.03M)(46.41M)132.33M(65.00M)[{"date":"2020-12-31","value":29.02,"profit":true},{"date":"2021-12-31","value":-49.9,"profit":false},{"date":"2022-12-31","value":-35.07,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-49.12,"profit":false}]
Income From Continuous Operations36.74M(71.20M)(46.41M)132.33M(65.00M)[{"date":"2020-12-31","value":27.76,"profit":true},{"date":"2021-12-31","value":-53.8,"profit":false},{"date":"2022-12-31","value":-35.07,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-49.12,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income36.74M(66.03M)(46.41M)132.33M(65.00M)[{"date":"2020-12-31","value":27.76,"profit":true},{"date":"2021-12-31","value":-49.9,"profit":false},{"date":"2022-12-31","value":-35.07,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-49.12,"profit":false}]
EPS (Diluted)0.95(1.90)(1.22)3.09(1.13)[{"date":"2020-12-31","value":30.74,"profit":true},{"date":"2021-12-31","value":-61.49,"profit":false},{"date":"2022-12-31","value":-39.48,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-36.57,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VYGR
Cash Ratio 5.87
Current Ratio 6.10

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VYGR
ROA (LTM) -15.04%
ROE (LTM) -27.61%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VYGR
Debt Ratio Lower is generally better. Negative is bad. 0.23
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.77

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VYGR
Trailing PE NM
Forward PE NM
P/S (TTM) 2.83
P/B 0.70
Price/FCF NM
EV/R 0.14
EV/Ebitda 2.59
PEG NM

FAQs

What is Voyager Therapeutics Inc share price today?

Voyager Therapeutics Inc (VYGR) share price today is $3.4

Can Indians buy Voyager Therapeutics Inc shares?

Yes, Indians can buy shares of Voyager Therapeutics Inc (VYGR) on Vested. To buy Voyager Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VYGR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Voyager Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Voyager Therapeutics Inc (VYGR) via the Vested app. You can start investing in Voyager Therapeutics Inc (VYGR) with a minimum investment of $1.

How to invest in Voyager Therapeutics Inc shares from India?

You can invest in shares of Voyager Therapeutics Inc (VYGR) via Vested in three simple steps:

  • Click on Sign Up or Invest in VYGR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Voyager Therapeutics Inc shares
What is Voyager Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Voyager Therapeutics Inc (VYGR) is $9.55. The 52-week low price of Voyager Therapeutics Inc (VYGR) is $2.75.

What is Voyager Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Voyager Therapeutics Inc (VYGR) is 0.70

What is the Market Cap of Voyager Therapeutics Inc?

The market capitalization of Voyager Therapeutics Inc (VYGR) is $181.50M

What is Voyager Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Voyager Therapeutics Inc is VYGR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top